Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2699298 | 0.83 | MET (0.43) | METCYP3A4KCNH2 | |
| SCHEMBL9910396 | 0.72 | MET (0.81) | METCYP3A4KCNH2 | |
| SCHEMBL9924321 | 0.70 | MET (0.53) | METBRD4CYP3A4KCNH2 | |
| SCHEMBL11625093 | 0.69 | KDM4E (0.51) | METMEN1KMT2A | |
| SCHEMBL9924282 | 0.66 | MET (0.53) | METMEN1KMT2A | |
| SCHEMBL14558238 | 0.65 | APAF1 (0.43) | — | |
| SCHEMBL12910648 | 0.65 | KDM4E (0.56) | METBRD4MEN1KMT2A | |
| SCHEMBL12891181 | 0.65 | BRD4 (0.42) | METBRD4MEN1KMT2A | |
| SCHEMBL937132 | 0.64 | MET (0.59) | METCYP3A4MEN1KMT2A | |
| SCHEMBL11626491 | 0.62 | CYP1A2 (0.71) | METCYP3A4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885BRD4 3499/4885CYP3A4 118/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885BRD4 3499/4885CYP3A4 118/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885BRD4 3499/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.